The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group
Abstract
Purpose: The purpose of the study was to assess the contribution of age and disease variables to the outcome of untreated patients with acute myeloid leukemia (AML) receiving varying intensive induction chemotherapy. Patients and Methods: Patients 16 to 85 years of age with primary AML, known karyotype, and uniform postremission chemotherapy enrolled onto two consecutive trials were eligible and were randomly assigned to induction either with a standard-dose (cytarabine, daunorubicin, and 6-thioguanine) and a high-dose (cytarabine and mitoxantrone) combination, or with two courses of the high-dose combination. Subgroups were defined by karyotype, nucleophosmin and FLT3 mutation, WBC count, serum lactate dehydrogenase, and residual blasts. Results: In 1,284 patients, the overall survival at 4 years in those younger and older than 60 years was 37% versus 16% (P < .001) and the ongoing remission duration was 46% versus 22% (P < .001). Similar age-related differences in outcome were found for all defined subgroups. No difference in outcome according to randomly assigned treatment regimen was observed in any age group or prognostic subset. Regarding prognostic subgroups, molecular factors were also considered. Conclusion: Under harmonized conditions, older and younger patients with AML show modest differences in their risk profiles and equally no dose response to intensified chemotherapy. Their observed fundamental difference in outcome across all subgroups remains unexplained. Further molecular investigation may elucidate the age effect in AML and identify new targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Cited by
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
Metzeler, K. H., Herold, T., Rothenberg-Thurley, M., Amler, S., Sauerland, M. C., Görlich, D., Schneider, S., Konstandin, N. P., Dufour, A., Bräundl, K., et al. (2016) · Blood · doi:10.1182/blood-2016-01-693879 · Cited by 529
Self-citation(2013) · doi:10.1158/2159-8290.cd-13-0350 · Cited by 393
Metadata
- Authors
- Büchner, T., Berdel, W. E., Haferlach, C., Haferlach, T., Schnittger, S., Müller-Tidow, C., Braess, J., Spiekermann, K., Kienast, J., Staib, P., Grüneisen, A., Kern, W., Reichle, A., Maschmeyer, G., Aul, C., Lengfelder, E., Sauerland, M.-C., Heinecke, A., Wörmann, B., & Hiddemann, W.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-01-01
- Volume
- 27
- Issue
- 1
- Pages
- 61-69
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2097035477
- Cited by
- 338
- References
- 1
- FWCI
- 12.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group. https://app.cochat.ai/papers/10.1200/jco.2007.15.4245
- The paper
- Büchner, T., Berdel, W. E., Haferlach, C., Haferlach, T., Schnittger, S., Müller-Tidow, C., Braess, J., Spiekermann, K., Kienast, J., Staib, P., Grüneisen, A., Kern, W., Reichle, A., Maschmeyer, G., Aul, C., Lengfelder, E., Sauerland, M.-C., Heinecke, A., Wörmann, B., & Hiddemann, W. (2009). Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.15.4245
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
